The NPPA has revised the MRPs of 543 cancer drug brands and pack sizes. Steep generic price cuts contrast with unchanged rates for costly originator. The Supreme Court has questioned the Centre over the huge gap between the procurement cost and MRP of cancer medicines, asking why more drugs are not brought under price control.